 | This article needs additional citations for verification. (July 2009) |
| Combination of | |
|---|---|
| Lidocaine | Local anesthetic |
| Prilocaine | Local anesthetic |
| Clinical data | |
| Trade names | Emla, Fortacin, Senstend, others |
| AHFS/Drugs.com | Micromedex Detailed Consumer Information |
| License data |
|
| Routes of administration | Topical |
| ATC code |
|
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| KEGG | |
| CompTox Dashboard (EPA) | |
  (what is this?) (verify) | |
Lidocaine/prilocaine is a eutectic mixture of equal quantities (by weight) of lidocaine and prilocaine. A 5% emulsion preparation, containing 2.5% each of lidocaine/prilocaine, is marketed by APP Pharmaceuticals under the trade name EMLA (an abbreviation for Eutectic Mixture of Local Anesthetics).[5] As a spray, it is marketed under the name Tempe (topical eutectic-like mixture for premature ejaculation) (PSD502) that can be used by men to help with premature ejaculation. The spray is manufactured by Plethora Solutions and branded as Fortacin in the UK and Recordati in the EU.[6]
- ^ "Emla Cream 5% (for 5 g and pre-medication packs) - Summary of Product Characteristics (SmPC)". (emc). 4 May 2017. Retrieved 27 September 2020.
- ^ "Fortacin - Summary of Product Characteristics (SmPC)". (emc). 14 November 2018. Retrieved 27 September 2020.
- ^ "Nulbia 5% cream - Summary of Product Characteristics (SmPC)". (emc). 18 December 2017. Retrieved 27 September 2020.
- ^ "List of nationally authorised medicinal products" (PDF). ema.europa.eu. 1 December 2022. Retrieved 13 June 2023.
- ^ Pesaturo KA, Matthews M (2009). "Topical Anesthesia Use in Children: Eutectic Mixture of Local Anesthetics". US Pharm. 34 (3): HS-4. Retrieved 7 January 2014.
- ^ Dinsmore WW, Wyllie MG (April 2009). "PSD502 improves ejaculatory latency, control and sexual satisfaction when applied topically 5 min before intercourse in men with premature ejaculation: results of a phase III, multicentre, double-blind, placebo-controlled study". BJU International. 103 (7): 940–949. doi:10.1111/j.1464-410X.2009.08456.x. PMID 19245438. S2CID 205540753.